Seeking Alpha·1d ago
Pfizer Inc. (PFE) Presents at U.S. All Stars Conference TranscriptPfizer Inc. (PFE) Presents at U.S. All Stars Conference Transcript
Pfizer's revenue is stabilizing after the COVID cliff, with Q2 2026 growth of 2.6% YoY and gross margin expanding to 72.8% from 64.3% a year earlier, reflecting a favorable product mix. However, the company faces a significant patent cliff and IRA pricing pres...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth turned positive at 2.6% YoY in Q2 2026, with gross margin expanding to 72.8% from 64.3% a year earlier, though net income swung to a -$246M loss due to below-the-line items.
Pfizer's oncology drugs like Padcev, Lorbrena, and Talzenna are performing well, with pivotal trials for weight-loss drugs planned for 2026.
The company's strategy includes acquiring and developing new products, which could enhance revenue.
Technical analyses suggest a potential stabilization above $25.00, with targets of $28.00-$29.00.
Key products like Eliquis and Ibrance will lose patent protection between 2026 and 2030, potentially impacting revenues by $1.5 billion in 2026.
Sales from the COVID-19 vaccine and antiviral are expected to decline further in 2026, affecting overall revenue.
Competition in breast cancer treatments and obesity drugs from companies like Eli Lilly and Novo Nordisk could erode market share.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 4, 2026 | $0.77+12.9% vs $0.68 | $15.0B+4.4% vs $14.4B |
Q2 2026 May 5, 2026 | $0.75+3.9% vs $0.72 | $14.5B+4.4% vs $13.8B |
Q1 2026 Feb 3, 2026 | $0.66+16.4% vs $0.57 | $17.6B+4.2% vs $16.8B |
Q4 2025 Nov 4, 2025 | $0.87+37.4% vs $0.63 | $16.7B+0.9% vs $16.5B |
Pfizer Inc. (PFE) Presents at U.S. All Stars Conference Transcript
Eli Lilly's yield of 0.6% looks minimal, but that's only because of how incredibly well the stock has performed. Pfizer has one of the highest yields on the S&P 500, but many investors are fearful that it's too risky.
Pfizer remains a Buy, with valuation reflecting LOE risks and attractive risk-reward as the company executes on post-LOE growth strategies. PFE delivered a strong quarter, raising revenue guidance to $61.5B, driven by non-COVID portfolio strength and past acquisitions. Operational efficiency programs target $9.7B in cost savings through 2029, supporting ongoing R&D investment, deleveraging, and a robust 6.22% dividend yield.
Pfizer CEO Albert Bourla plans to attend U.S. President Donald Trump's state dinner for Chinese President Xi Jinping on Thursday evening, according to a source familiar with the matter on Tuesday.
Benchmark PFE against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Pfizer Inc. (PFE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $27.93 | $159.19B | 20.54 | -1.65% | 12.42% | 8.87% | 6.15% | |
| $269.19 | $648B | 24.41 | 6.05% | 21.58% | 25.75% | — | |
| $150.92 | $372.73B | 20.73 | 1.18% | 4.78% | 6.59% | — | |
| $265.32 | $468.77B | 111.95 | 8.57% | 9.81% | — | — | |
| $1170.48 | $1.1T | 51.00 | 44.7% | 33.53% | 92.53% | — | |
| $62.25 | $127.12B | 18.04 | -0.22% | 18.87% | 46.69% | — |
Pfizer Inc. (PFE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Pfizer Inc. (PFE) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 4, 2026·SEC
Jun 18, 2026·SEC
Jun 18, 2026·SEC
Get notified when PFE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Pfizer Inc. (PFE) stock FAQ — growth, dividends, profitability & financials explained
Pfizer Inc. (PFE) reported $63.70B in revenue for fiscal year 2025. This represents a 463% increase from $11.31B in 1996.
Pfizer Inc. (PFE) saw revenue decline by 1.6% over the past year.
Yes, Pfizer Inc. (PFE) is profitable, generating $4.33B in net income for fiscal year 2025 (12.4% net margin).
Yes, Pfizer Inc. (PFE) pays a dividend with a yield of 6.15%. This makes it attractive for income-focused investors.
Pfizer Inc. (PFE) has a return on equity (ROE) of 8.9%. This is below average, suggesting room for improvement.
Pfizer Inc. (PFE) generated $10.99B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
